The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...

Also, Penn settled a lawsuit with the German drug manufacturer BioNTech, which, with Pfizer, made the COVID vaccine using ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

EST: Adds details about Penn settlement BioNTech (NASDAQ:BNTX) announced Friday two separate agreements worth more than $1B ...

Pfizer has agreed to reimburse BioNTech for $364.5 million of the claimed royalties paid to NIH and $170.0 million of the claimed royalties paid to the University of Pennsylvania. Write to Dean Seal ...

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...

BioNTech agreed to pay $791.5 million to the U.S. National Institutes of Health (NIH) and $467 million to the University of ...

BioNTech said partner Pfizer will reimburse it for up to $170 million of the royalties payable to Penn and $364.5 million of the royalties paid to the National Institutes of Health (NIH ...

Concurrently, BioNTech (BNTX) announced a settlement agreement worth $467M with Penn to resolve a lawsuit filed by the university over royalty claims related to the COVID-19 shot. The deal ...

Penn has agreed to dismiss with prejudice the litigation Penn filed against the Company and its former subsidiary, BioNTech RNA Pharmaceuticals, in the U.S. District Court for the Eastern District ...